Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 107 articles: HTML format

Single Articles

November 2021
1. ENNIS RD, Vapiwala N
   The Fallacy of the Consultation and Informed Consent Process in Radiation Oncology Through the Lens of Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2021;111:643-646.
   PubMed    
   
   
   October 2021
2. MUSUNURU HB, Cheung P, Vesprini D, Liu SK, et al
   Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost.
   Int J Radiat Oncol Biol Phys. 2021 Oct 9. pii: S0360-3016(21)02899.
   PubMed     Abstract available
   
   
   September 2021
3. JONES CU, Pugh SL, Sandler HM, Chetner MP, et al
   Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.
   Int J Radiat Oncol Biol Phys. 2021 Sep 1. pii: S0360-3016(21)02724.
   PubMed     Abstract available
   
   
   
4. NAGAR H, Spratt DE
   Prostate SBRT Dose Escalation (9 Gyx5, 13.3 Gyx3, 24 Gyx1): Are We Making Progress?
   Int J Radiat Oncol Biol Phys. 2021;111:110-112.
   PubMed    
   
   
   August 2021
5. NUIJENS AC, Oei AL, van Oorschot B, Visser J, et al
   Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.
   Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02708.
   PubMed     Abstract available
   
   
   
6. FERREIRA MR, Sands CJ, Li JV, Andreyev JN, et al
   Impact of pelvic radiotherapy for prostate cancer on global metabolic profiles and microbiota-driven gastrointestinal late side-effects: a longitudinal observational study.
   Int J Radiat Oncol Biol Phys. 2021 Aug 2. pii: S0360-3016(21)02626.
   PubMed     Abstract available
   
   
   
7. LEITE ETT, Ramos CCA, Moraes FY
   In Reply to Fiorino et al.
   Int J Radiat Oncol Biol Phys. 2021;110:1549-1550.
   PubMed    
   
   
   
8. ARAI TJ, Yang DM, Campbell JW 3rd, Chiu T, et al
   Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?
   Int J Radiat Oncol Biol Phys. 2021;110:1519-1529.
   PubMed     Abstract available
   
   
   
9. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
   Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
   Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
   PubMed     Abstract available
   
   
   July 2021
10. PARZEN JS, Hamstra DA
    Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience.
    Int J Radiat Oncol Biol Phys. 2021;110:1129-1131.
    PubMed    
    
    
    
11. CHOUDHURY A, Henry Md Frcr A, Mitin Md PhD T, Chen Md Mph R, et al
    Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team.
    Int J Radiat Oncol Biol Phys. 2021;110:1114-1121.
    PubMed    
    
    
    
12. EFSTATHIOU JA, Kamran SC, Spratt DE
    Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming.
    Int J Radiat Oncol Biol Phys. 2021;110:1098-1100.
    PubMed    
    
    
    
13. PARKER C
    Timing of Postoperative Radiation Therapy After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2021;110:1132-1134.
    PubMed    
    
    
    
14. YANG Y, Vargas CE, Bhangoo RS, Wong WW, et al
    Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT).
    Int J Radiat Oncol Biol Phys. 2021;110:1189-1199.
    PubMed     Abstract available
    
    
    
15. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
    Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
    PubMed     Abstract available
    
    
    
16. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
    First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
    PubMed     Abstract available
    
    
    
17. KISHAN AU, Collins SP
    Quality of Life After Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;110:727-730.
    PubMed    
    
    
    
18. MOHAMAD O, Feng F
    Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
    Int J Radiat Oncol Biol Phys. 2021;110:634-635.
    PubMed    
    
    
    
19. BELKACEMI Y, Coraggio G, Loganadane G
    Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
    Int J Radiat Oncol Biol Phys. 2021;110:631-632.
    PubMed    
    
    
    
20. RANS K, De Meerleer G, Joniau S, Baten A, et al
    In Regard to Zelefsky et al.
    Int J Radiat Oncol Biol Phys. 2021;110:910-911.
    PubMed    
    
    
    
21. WALSHAW RC, Hoskin PJ, Choudhury A
    Can Hypofractionation and Immune Modulation Coexist?
    Int J Radiat Oncol Biol Phys. 2021;110:742-744.
    PubMed    
    
    
    
22. WALLIS CJD, Klotz L, Satkunasivam R, Klaassen Z, et al
    Not So "Active" Surveillance.
    Int J Radiat Oncol Biol Phys. 2021;110:716-717.
    PubMed    
    
    
    
23. SHORTALL J, Palma G, Mistry H, Vasquez Osorio E, et al
    Flogging a Dead Salmon? Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2021;110:696-699.
    PubMed    
    
    
    
24. CHEN RC
    A Trans-Atlantic Voyage of Extended ADT With Local Radiation.
    Int J Radiat Oncol Biol Phys. 2021;110:633.
    PubMed    
    
    
    
25. VAN DAMS R, Jiang NY, Fuller DB, Loblaw A, et al
    Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
    Int J Radiat Oncol Biol Phys. 2021;110:731-737.
    PubMed     Abstract available
    
    
    
26. HSU IC, Rodgers JP, Shinohara K, Purdy J, et al
    Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
    Int J Radiat Oncol Biol Phys. 2021;110:700-707.
    PubMed     Abstract available
    
    
    June 2021
27. BRAND DH, Bruningk SC, Wilkins A, Fernandez K, et al
    Estimates of Alpha/Beta (alpha/beta) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:596-608.
    PubMed     Abstract available
    
    
    May 2021
28. NITHIYANANTHAN K, Creighton N, Currow D, Martin JM, et al
    Population-Level Uptake of Moderately Hypofractionated Definitive Radiotherapy in the Treatment of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 8. pii: S0360-3016(21)00460.
    PubMed     Abstract available
    
    
    
29. HARA D, Tao W, Totiger T, Pourmand A, et al
    Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA).
    Int J Radiat Oncol Biol Phys. 2021 May 5. pii: S0360-3016(21)00459.
    PubMed     Abstract available
    
    
    
30. WANG K, Mavroidis P, Royce TJ, Falchook AD, et al
    Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
    Int J Radiat Oncol Biol Phys. 2021;110:237-248.
    PubMed     Abstract available
    
    
    April 2021
31. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
    OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
    Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
    PubMed     Abstract available
    
    
    
32. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
    FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
    Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.
    PubMed    
    
    
    
33. YAMAZAKI H, Suzuki G, Aibe N, Yoshida K, et al
    Posterior Margins in Prostate Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1657-1658.
    PubMed    
    
    
    
34. MITCHELL D, Jain S
    Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?
    Int J Radiat Oncol Biol Phys. 2021;109:1230-1231.
    PubMed    
    
    
    
35. LEITE ETT, Ramos CCA, Ribeiro VAB, Salvajoli BP, et al
    Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:1263-1270.
    PubMed     Abstract available
    
    
    
36. FU SY, Chen FH, Wang CC, Yu CF, et al
    Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
    Int J Radiat Oncol Biol Phys. 2021;109:1547-1558.
    PubMed     Abstract available
    
    
    
37. ROBIN S, Jolicoeur M, Palumbo S, Zilli T, et al
    Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1243-1253.
    PubMed     Abstract available
    
    
    March 2021
38. FOLKERT MR, Zelefsky MJ, Hannan R, Desai NB, et al
    A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 19. pii: S0360-3016(21)00285.
    PubMed     Abstract available
    
    
    
39. MAGLI A, Farneti A, Faiella A, Ferriero M, et al
    Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 18. pii: S0360-3016(21)00287.
    PubMed     Abstract available
    
    
    
40. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
    Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2021;109:718-725.
    PubMed     Abstract available
    
    
    
41. SHAHI J, Poon I, Ung YC, Tsao M, et al
    Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:764-774.
    PubMed     Abstract available
    
    
    February 2021
42. BUBLEY GJ, Kaplan I, Bhatt R, Taplin ME, et al
    Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.
    Int J Radiat Oncol Biol Phys. 2021 Feb 23. pii: S0360-3016(21)00205.
    PubMed     Abstract available
    
    
    
43. KUBES J, Haas A, Vondracek V, Andrlik M, et al
    Ultra-hypofractionated proton radiotherapy in the treatment of low- and intermediate-risk prostate cancer - 5-years outcomes.
    Int J Radiat Oncol Biol Phys. 2021 Feb 12. pii: S0360-3016(21)00189.
    PubMed     Abstract available
    
    
    
44. VAPIWALA N, Wong JK, Handorf E, Paly J, et al
    A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00117.
    PubMed     Abstract available
    
    
    
45. SUD S, Gerringer BC, Wacaser B, Tan X, et al
    Under-ascertainment of clinically-meaningful symptoms during prostate cancer radiation therapy - does this vary by patient characteristics?
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00108.
    PubMed     Abstract available
    
    
    January 2021
46. ROY S, Grimes S, Morgan SC, Eapen L, et al
    Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jan 29. pii: S0360-3016(21)00092.
    PubMed     Abstract available
    
    
    
47. CHEN RC, Prime SG, Basak R, Moon DH, et al
    Receipt of guideline-recommended surveillance in a population-based cohort of active surveillance prostate cancer patients.
    Int J Radiat Oncol Biol Phys. 2021 Jan 13. pii: S0360-3016(21)00034.
    PubMed     Abstract available
    
    
    December 2020
48. GARIN O, Suarez JF, Guedea F, Pont A, et al
    Comparative Effectiveness Research in Localized Prostate Cancer: a 10-Year follow-up Cohort Study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 31. pii: S0360-3016(20)34728.
    PubMed     Abstract available
    
    
    
49. CHEN WC, Li Y, Lazar A, Altan A, et al
    Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.
    Int J Radiat Oncol Biol Phys. 2020 Dec 29. pii: S0360-3016(20)34730.
    PubMed     Abstract available
    
    
    
50. TANG C, Lei X, Smith GL, Pan HY, et al
    Influence of Geography on Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2020 Dec 11. pii: S0360-3016(20)34595.
    PubMed     Abstract available
    
    
    
51. PARRY MG, Nossiter J, Sujenthiran A, Cowling TE, et al
    Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 3. pii: S0360-3016(20)34545.
    PubMed     Abstract available
    
    
    
52. DEE EC, Muralidhar V, Arega MA, Kishan AU, et al
    Factors influencing non-completion of radiotherapy among men with localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Dec 1. pii: S0360-3016(20)34604.
    PubMed     Abstract available
    
    
    
53. JANI A, Schreibmann E, Goyal S, Raghuveer H, et al
    Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine ((18)F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:1397.
    PubMed    
    
    
    
54. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
    Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
    PubMed     Abstract available
    
    
    November 2020
55. KOONTZ BF, Hoffman KE, Halabi S, Healy P, et al
    Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 28. pii: S0360-3016(20)34599.
    PubMed     Abstract available
    
    
    
56. WAGES NA, Sanders JC, Smith A, Wood S, et al
    Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial.
    Int J Radiat Oncol Biol Phys. 2020 Nov 20. pii: S0360-3016(20)34497.
    PubMed     Abstract available
    
    
    
57. SPENCER KL, Tree AC
    Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:927-929.
    PubMed    
    
    
    
58. DESAI NB, Garant A, Hannan R, Folkert MR, et al
    Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation.
    Int J Radiat Oncol Biol Phys. 2020;108:914-916.
    PubMed    
    
    
    
59. BOHMER D, Hocht S, Wiegel T
    Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
    Int J Radiat Oncol Biol Phys. 2020;108:903-904.
    PubMed    
    
    
    
60. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
    A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
    PubMed     Abstract available
    
    
    
61. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
    Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
    Int J Radiat Oncol Biol Phys. 2020;108:936-940.
    PubMed     Abstract available
    
    
    
62. TAKAGI M, Demizu Y, Fujii O, D KT, et al
    Proton Therapy for Localized Prostate Cancer: Long-term Results in 2,021 Patients.
    Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34493.
    PubMed     Abstract available
    
    
    
63. GOGINENI E, Rana Z, Soberman D, Sidiqi B, et al
    Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 7. pii: S0360-3016(20)34489.
    PubMed     Abstract available
    
    
    
64. BERK L, Lopez Alfonso JC
    Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer In Regard to Vogelius et al.
    Int J Radiat Oncol Biol Phys. 2020;108:834.
    PubMed    
    
    
    
65. THOMPSON AB, Hamstra DA
    Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:644-648.
    PubMed    
    
    
    
66. VOGELIUS IR, Bentzen SM
    In Reply to Berk and Alfonso.
    Int J Radiat Oncol Biol Phys. 2020;108:834-835.
    PubMed    
    
    
    
67. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed     Abstract available
    
    
    
68. MAO X, Pineau J, Keyes R, Enger SA, et al
    RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
    Int J Radiat Oncol Biol Phys. 2020;108:802-812.
    PubMed     Abstract available
    
    
    October 2020
69. HOFFMAN KE
    Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:340.
    PubMed    
    
    
    
70. LEEMAN JE, Nguyen PL
    Less Is More During COVID 19.
    Int J Radiat Oncol Biol Phys. 2020;108:339.
    PubMed    
    
    
    
71. SPRATT DE
    Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion.
    Int J Radiat Oncol Biol Phys. 2020;108:338-339.
    PubMed    
    
    
    
72. MOHAMAD O, Roach M 3rd
    Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:337.
    PubMed    
    
    
    
73. LING DC, Vargo JA, Beriwal S
    Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
    Int J Radiat Oncol Biol Phys. 2020;108:390-393.
    PubMed    
    
    
    
74. ZAORSKY NG
    Prostate and Pelvis on Pause Pending a Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:341-342.
    PubMed    
    
    
    
75. KOONTZ BF
    Through COVID-Colored Glasses: New Perspectives on Same Data.
    Int J Radiat Oncol Biol Phys. 2020;108:338.
    PubMed    
    
    
    September 2020
76. SANDERS JW, Venkatesan AM, Levitt CA, Bathala T, et al
    Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study.
    Int J Radiat Oncol Biol Phys. 2020 Sep 24. pii: S0360-3016(20)34342.
    PubMed     Abstract available
    
    
    
77. SPRATT DE, Tward JD
    Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Sep 11. pii: S0360-3016(20)31252.
    PubMed    
    
    
    
78. ROYCE TJ, Mavroidis P, Wang K, Falchook AD, et al
    Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Sep 5. pii: S0360-3016(20)34102.
    PubMed     Abstract available
    
    
    
79. 
    Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Rad
    Int J Radiat Oncol Biol Phys. 2020;108:328.
    PubMed    
    
    
    August 2020
80. HALL WA, Paulson E, Davis BJ, Spratt DE, et al
    NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34124.
    PubMed     Abstract available
    
    
    
81. DEEK MP, Taparra K, Dao D, Chan L, et al
    Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 13. pii: S0360-3016(20)34120.
    PubMed     Abstract available
    
    
    
82. PALY J, Horwitz EM
    Less Is More: Treatment of Locally Advanced Small Cell Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;107:865-866.
    PubMed    
    
    
    
83. DALWADI SM, Zhu A
    Big Small Cell Dilemma.
    Int J Radiat Oncol Biol Phys. 2020;107:863-864.
    PubMed    
    
    
    
84. ABU-GHEIDA I, Bathala TK, Maldonado JA, Khan M, et al
    Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers.
    Int J Radiat Oncol Biol Phys. 2020;107:982-985.
    PubMed     Abstract available
    
    
    July 2020
85. PARRY MG, Nossiter J, Cowling TE, Sujenthiran A, et al
    Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.
    Int J Radiat Oncol Biol Phys. 2020 Jul 24. pii: S0360-3016(20)31450.
    PubMed     Abstract available
    
    
    
86. MITIN T, Choudhury A
    Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
    Int J Radiat Oncol Biol Phys. 2020;107:609-612.
    PubMed    
    
    
    
87. WANG Y, Chen H
    In Reply to Ghadjar et al.
    Int J Radiat Oncol Biol Phys. 2020;107:856.
    PubMed    
    
    
    
88. MYLONA E, Ebert M, Kennedy A, Joseph D, et al
    Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer Radiotherapy: validation of voxel-based models in an independent population.
    Int J Radiat Oncol Biol Phys. 2020 Jul 13. pii: S0360-3016(20)31417.
    PubMed     Abstract available
    
    
    
89. BERGAMIN S, Eade T, Kneebone A, Booth J, et al
    Interim results of a prospective PSMA-directed focal stereotactic re-irradiation trial for locally recurrent prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 10. pii: S0360-3016(20)31412.
    PubMed     Abstract available
    
    
    
90. SANDERS JW, Lewis GD, Thames HD, Kudchadker RJ, et al
    Machine segmentation of pelvic anatomy in MRI-assisted radiosurgery (MARS) for prostate cancer brachytherapy.
    Int J Radiat Oncol Biol Phys. 2020 Jul 4. pii: S0360-3016(20)31396.
    PubMed     Abstract available
    
    
    
91. VAN SCHIE MA, Janssen TM, Eekhout D, Walraven I, et al
    Knowledge-based assessment of focal dose escalation treatment plans in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 3. pii: S0360-3016(20)31392.
    PubMed     Abstract available
    
    
    June 2020
92. ROY S, Grimes S, Eapen L, Spratt DE, et al
    Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
    PubMed     Abstract available
    
    
    
93. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
    Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
    PubMed     Abstract available
    
    
    
94. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
    Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
    PubMed     Abstract available
    
    
    
95. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
    Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
    PubMed     Abstract available
    
    
    
96. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
    Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
    PubMed    
    
    
    
97. 
    Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Res
    Int J Radiat Oncol Biol Phys. 2020;107:390.
    PubMed    
    
    
    
98. YUCE SARI S, Elmali A, Arslan S, Ozyigit G, et al
    In Regard to Aksnessaetheret al.
    Int J Radiat Oncol Biol Phys. 2020;107:387-388.
    PubMed    
    
    
    
99. CHIN S, Fatimilehin A, Walshaw R, Argarwal A, et al
    Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
    Int J Radiat Oncol Biol Phys. 2020;107:288-296.
    PubMed     Abstract available
    
    
    May 2020
100. GHADJAR P, Zwahlen DR, Hayoz S, Aebersold DM, et al
     In Regard to Qi et al.
     Int J Radiat Oncol Biol Phys. 2020;107:224-225.
     PubMed    
     
     
     
101. GUNTHER JR
     Involved-Site Radiation Therapy if Minimal Toxicity.
     Int J Radiat Oncol Biol Phys. 2020;107:20-21.
     PubMed    
     
     
     
102. ALAYED Y, Davidson M, Liu S, Chu W, et al
     Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
     Int J Radiat Oncol Biol Phys. 2020;107:136-142.
     PubMed     Abstract available
     
     
     April 2020
103. QIN H, Zhang V, Bok RA, Santos RD, et al
     Simultaneous metabolic and perfusion imaging using hyperpolarized (13)C MRI can evaluate early and dose-dependent responses to radiotherapy in a prostate cancer mouse model.
     Int J Radiat Oncol Biol Phys. 2020 Apr 24. pii: S0360-3016(20)31042.
     PubMed     Abstract available
     
     
     
104. MCCLELLAND S 3RD, Petereit DG
     The Advanced Alternative Payment Model: Catalyst for Prostate Brachytherapy Adoption?
     Int J Radiat Oncol Biol Phys. 2020;106:1104-1105.
     PubMed    
     
     
     
105. WILKINS A, Naismith O, Brand D, Fernandez K, et al
     Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
     Int J Radiat Oncol Biol Phys. 2020;106:928-938.
     PubMed     Abstract available
     
     
     March 2020
106. KEALL P, Nguyen DT, O'Brien R, Hewson E, et al
     Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial.
     Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30937.
     PubMed     Abstract available
     
     
     
107. ACHARD V, Zilli T
     In Regard to Qi et al.
     Int J Radiat Oncol Biol Phys. 2020;106:887-888.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: